Oslo, Norway, 26 June 2020: Reference is made to the previous stock exchange
notices where Photocure ASA ("Photocure" or the "Company") announced the
allocation of 2,500,000 shares at a subscription price of NOK 76 per share,
raising gross proceeds of approx. NOK 190,000,000 in a private placement (the
"Private Placement"). The shares will be listed on the Oslo Stock Exchange and
are tradeable from today, 26 June 2020.

The share capital increase pertaining to the issuance of the 2,500,000 new
shares has now been registered with the Norwegian Register of Business
Enterprises. the Company's new registered share capital is 13,305,010.00,
divided into 26,610,020 shares, each with a par value of NOK 0.50 per share.
Each share represents one vote in the Company's general meeting.



About Photocure ASA

Photocure: The Bladder Cancer Company delivers transformative solutions to
improve the lives of bladder cancer patients. Our unique technology, making
cancer cells glow bright pink, has led to better health outcomes for patients
worldwide. Photocure is headquartered in Oslo, Norway and listed on the Oslo
Stock Exchange (OSE: PHO). For more information, please visit us at
www.photocure.com, www.hexvix.com, www.cysview.com



This information is subject to the disclosure requirements pursuant to Section 5
-12 the Norwegian Securities Trading Act.

For further information, please contact:

Dan Schneider
President and CEO
Tel: + 1-609 759-6515
Email: ds@photocure.com

Erik Dahl
Chief Financial Officer
Tel: +47 450 55 000
Email: ed@photocure.no